Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Phibro Animal Health Corporation (PAHC) Share Price
News headlines about Phibro Animal Health Corporation (NASDAQ:PAHC) have been trending somewhat positive this week, Alpha One reports. Alpha One, a subsidiary of Accern, identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Phibro Animal Health Corporation earned a daily sentiment score of 0.13 on Alpha One’s scale. Alpha One also gave media headlines about the company an impact score of 42 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Alpha One Sentiment’s rankings:
- President and CEO of Phibro Animal Health Corporatio (NASDAQ:PAHC), Bendheim Jack, sells 16,000 shares worth $557,440 (empowerednews.net)
- Health Care Battle Rages On: 2 MedTech Stocks to Buy (finance.yahoo.com)
- Phibro Animal Health Corporation (PAHC) Major Shareholder Bfi Co., Llc Sells 48,000 Shares (americanbankingnews.com)
- Financial Comparison: Zoetis (ZTS) and Phibro Animal Health Corporation (PAHC) (americanbankingnews.com)
- Phibro Animal Health Corporation (PAHC) Lowered to Buy at BidaskClub (americanbankingnews.com)
Phibro Animal Health Corporation (NASDAQ:PAHC) traded up 3.30% during midday trading on Friday, hitting $36.00. 371,077 shares of the company traded hands. The firm has a market capitalization of $1.43 billion, a PE ratio of 22.36 and a beta of 1.35. The stock’s 50-day moving average is $33.74 and its 200-day moving average is $29.57. Phibro Animal Health Corporation has a 12-month low of $17.96 and a 12-month high of $36.40.
Phibro Animal Health Corporation (NASDAQ:PAHC) last issued its quarterly earnings results on Monday, May 8th. The company reported $0.37 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.37. The company had revenue of $190 million for the quarter, compared to the consensus estimate of $185.90 million. Phibro Animal Health Corporation had a net margin of 8.49% and a return on equity of 54.68%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.38 EPS. Analysts anticipate that Phibro Animal Health Corporation will post $1.45 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 22nd. Investors of record on Wednesday, May 31st will be issued a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 1.11%. The ex-dividend date of this dividend is Friday, May 26th. Phibro Animal Health Corporation’s dividend payout ratio (DPR) is currently 24.69%.
A number of equities analysts recently commented on PAHC shares. BidaskClub lowered shares of Phibro Animal Health Corporation from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Credit Suisse Group lowered shares of Phibro Animal Health Corporation from an “outperform” rating to a “neutral” rating and lifted their target price for the company from $29.00 to $36.00 in a research note on Friday, June 2nd. Finally, Zacks Investment Research raised shares of Phibro Animal Health Corporation from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a research note on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $30.33.
TRADEMARK VIOLATION NOTICE: This report was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/06/16/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-phibro-animal-health-corp-pahc-stock-price-updated.html.
In other Phibro Animal Health Corporation news, Director Gerald K. Carlson sold 12,000 shares of the company’s stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $28.13, for a total transaction of $337,560.00. Following the sale, the director now directly owns 12,000 shares of the company’s stock, valued at $337,560. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gerald K. Carlson sold 63,338 shares of the company’s stock in a transaction dated Thursday, May 11th. The shares were sold at an average price of $33.31, for a total transaction of $2,109,788.78. Following the sale, the director now directly owns 50 shares in the company, valued at $1,665.50. The disclosure for this sale can be found here. Insiders sold a total of 367,296 shares of company stock worth $12,211,634 over the last three months. 48.09% of the stock is owned by insiders.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Receive News & Stock Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related stocks with our FREE daily email newsletter.